

FREEDOM OF INFORMATION REQUEST

RF23-496

Request:

Q1. How many haemophilia A patients are registered with your centre, and how many of these patients are classified as paediatric (age 17 and under).

Q2. In the last three months, how many Haemophilia A patients, including on-demand patients, have been treated with the following products?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Any other products

Q3. For patients treated with Advate in the last three months, please provide:

- the number of haemophilia A patients treated prophylactically
- the number of haemophilia A patients treated for any other reason (e.g. surgery, on-demand, breakthrough bleeds)

Q4. In the last three months, how many patients were treated with the following products for severe Haemophila A ONLY?

- Advate
- Adynovi
- Elocta
- Esperoct
- Factor Eight Inhibitor Bypass Activity (FEIBA)
- Hemlibra (standalone)
- Hemlibra in combination with any Factor VIII
- NovoEight
- NovoSeven RT
- Nuwiq
- Obizur
- Refacto AF
- Any other products



Response:

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1. Total patients: 144. Paediatric patients: 34.

2.

| | |
|--|-----|
| Advate | 11 |
| Adynovi | 0 |
| Elocta | 21 |
| Esperoct | <5* |
| Factor Eight Inhibitor Bypass Activity (FEIBA) | 0 |
| Hemlibra (standalone) | 28 |
| Hemlibra in combination with any Factor VIII | 10 |
| NovoEight | <5* |
| NovoSeven RT | <5* |
| Nuwiq | 0 |
| Obizur | 0 |
| Refacto AF | 6 |
| Any other products: DDAVP Octim | <5* |

3.

| | |
|--|---------------|
| The number of haemophilia A patients treated prophylactically | <5* |
| The number of haemophilia A patients treated for any other reason (e.g. surgery, on demand, breakthrough bleeds) | 9 (On Demand) |

4.

| | |
|--|-----|
| Advate | 7 |
| Adynovi | 0 |
| Elocta | 17 |
| Esperoct | <5* |
| Factor Eight Inhibitor Bypass Activity (FEIBA) | 0 |
| Hemlibra (standalone) | 25 |
| Hemlibra in combination with any Factor VIII | 10 |
| NovoEight | <5* |
| NovoSeven RT | <5* |
| Nuwiq | 0 |
| Obizur | 0 |
| Refacto AF | <5* |
| Any other products | 0 |



* EKHUFT is unable to confirm the exact number where fewer than five patients are recorded. Given the low number, we consider that disclosure of such information, which constitutes personal data, would contravene the first data protection principle under GDPR. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle, which in our view, would be breached by disclosure. We believe that not disclosing this information is in line with Sections 40(2) and 40(3) of the Freedom of Information Act 2000.

(DATE OF RESPONSE: 16 AUGUST 2023)

